Share chart Annexon, Inc.
Extended chart
Simple chart
About Annexon, Inc.
Annexon, Inc., биофармацевтическая компания, работающая на клинической стадии, открывает и разрабатывает лекарственные средства для лечения аутоиммунных и нейродегенеративных заболеваний. Он специализируется на лечении заболеваний тела, головного мозга и глаз. C1q компании является инициирующей молекулой классического пути комплемента, который нацелен на различные болезненные процессы, такие как опосредованное антителами аутоиммунное заболевание и опосредованная комплементом нейродегенерация. more detailsMain settings
| IPO date | 2020-07-24 |
|---|---|
| ISIN | US03589W1027 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Change price per day: | 0% (2.11) |
|---|---|
| Change price per week: | +0.9569% (2.09) |
| Change price per month: | +10.47% (1.91) |
| Change price per 3 month: | -20.38% (2.65) |
| Change price per half year: | -60.11% (5.29) |
| Change price per year: | -57.46% (4.96) |
| Change price per 3 year: | -36.06% (3.3) |
| Change price per year to date: | -59.66% (5.23) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 0 | 0 |
| P/BV | 2.4 | 6 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -42.67 | 0 |
| ROE, % | -50.84 | 0 |
| ROIC, % | -47.4 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.215 | 10 |
| Debt/Ratio | 0.0828 | 10 |
| Debt/Equity | 0.1944 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 112.2 | 10 |
| Yield EPS, % | -72.82 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| FMR, LLC | 9 685 401 | 12.36 |
| Bain Capital Life Sciences Investors, LLC | 8 061 719 | 10.29 |
| Alerce Investment Management, L.P. | 7 406 024 | 9.45 |
| BVF Inc. | 7 000 000 | 8.93 |
| Redmile Group, LLC | 5 503 190 | 7.02 |
| Adage Capital Partners GP L.L.C. | 4 999 975 | 6.38 |
| Logos Global Management LP | 4 950 000 | 6.32 |
| Blackrock Inc. | 3 318 579 | 4.23 |
| GMT Capital Corp | 3 020 474 | 3.85 |
| Ikarian Capital, LLC | 2 650 000 | 3.38 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 614.6k | 1958 (67 years) |
| Ms. Jennifer Lew | Executive VP, CFO & Corporate Secretary | 624.2k | 1973 (52 years) |
| Mr. Douglas Love Esq., J.D. | CEO, President & Director | 921.99k | 1968 (57 years) |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer | N/A | 1958 (67 years) |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 1961 (64 years) | |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer | 1971 (54 years) | |
| Mr. Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | ||
| Mr. Shikhar Agarwal M.B.A. | Senior VP & Head of Commercial | ||
| Dr. Sunil Mehta Pharm.D. | Senior VP of Medical Affairs |
About company
Address: United States, South San Francisco, 180 Kimball Way - Open in google maps, Open in yandex maps
Website: https://www.annexonbio.com
Website: https://www.annexonbio.com
